Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib

Breccia, Massimo; Palandri, Francesca; Iori, Anna Paola; Colaci, Elisabetta; Latagliata, Roberto; Castagnetti, Fausto; Torelli, Giovanni Fernando; Usai, Sara Veronica; Valle, Veronica; Martinelli, Giovanni; Rosti, Gianantonio; Foà, Robin; Baccarani, Michele

doi:10.1016/j.leukres.2009.04.036

Cited by 35 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, we considered that the use of dasatinib before the conditioning regimen might have adversely affected the gastrointestinal damage just after the second HSCT. Although several studies have shown that the use of second-generation TKIs before HSCT did not increase transplant-related toxicity, most of the patients in these studies had chronic myelogenous leukemia (CML) in the chronic phase [9][10][11]. The adverse effects of dasatinib may vary depending on the phase of the underlying leukemia.…”

Section: Discussionmentioning

confidence: 99%

Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

et al. 2010

View full text Add to dashboard Cite

Although allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), the prognosis of patients who relapse after allogeneic HSCT has been extremely poor. Dasatinib, a second-generation tyrosine kinase inhibitor, is a promising agent for the treatment of Ph-ALL. We report on a Ph-ALL patient who relapsed early after the first allogeneic HSCT, but achieved complete molecular remission with dasatinib alone. She remains in molecular remission 12 months after the second allogeneic HSCT. Dasatinib was generally well tolerated, but she developed myalgia, nausea and positive cytomegalovirus antigenemia. In addition, sudden-onset bloody diarrhea was observed 10 days after the second HSCT, which was possibly associated with the use of dasatinib in addition to the effect of the conditioning regimen and graft-versus-host disease. In conclusion, dasatinib is an effective agent for Ph-ALL with a poor prognosis, but may be associated with specific adverse events including opportunistic infection and gastrointestinal bleeding.

show abstract

Section: Discussionmentioning

confidence: 99%

Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Dose reduction of nilotinib due to hematological adverse events was based on the criteria of a Phase I/II study of nilotinib in Japan [4] obtaining complete cytogenetic response, by dasatinib therapy before SCT, might be effective in advanced CML patients. The current case further suggests that dasatinib therapy, followed by allo-SCT within a month, is also effective to reduce tumor burden in CML patients [11]. Further accumulation of experience regarding allo-SCT with optimal TKI pre-therapy for BCR-ABL mutations is necessary to improve the outcome of CML in the advanced phase.…”

Section: Discussionmentioning

confidence: 86%

Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR–ABL mutation

et al. 2010

View full text Add to dashboard Cite

We report a case of imatinib- and nilotinib-resistant Ph-positive chronic myeloid leukemia (CML) in blast crisis in which successful pretreatment with dasatinib with cord blood transplantation resulted in molecular remission. Before dasatinib therapy, the patient was found to have a F359V BCR-ABL mutation. He was treated with dasatinib for just 16, 19 days before allogeneic stem cell transplantation. This successful case indicates that reduction of tumor burden by second-generation tyrosine kinase inhibitors, in combination with stem cell transplantation, might be effective to treat CML, even in the advanced phase.

show abstract

“…TKIs-II have the potential advantage of rescuing patients after failure of imatinib therapy, and allowing these patients to undergo transplantation with a smaller disease bulk, which should improve disease control after HSCT [5]. Breccia et al administered pre-SCT dasatinib treatment to two CML-BC patients (treatment duration, 8 and 6 months), who achieved a CCyR and a CHR [12]. Similarly, Gotoh et al [13].…”

Section: Citationmentioning

confidence: 99%

Second Generation Tyrosine Kinase Inhibitors Combined With Allogeneic Hematopoietic Stem Cell Transplantation Improve the Prognosis of Patients with Chronic Myelogenous Leukemia in Blast Crisis

Yu¹,

Ding²,

Sun³

et al. 2017

J Stem Cell Res Ther

View full text Add to dashboard Cite

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib

Cited by 35 publications

References 15 publications

Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR–ABL mutation

Second Generation Tyrosine Kinase Inhibitors Combined With Allogeneic Hematopoietic Stem Cell Transplantation Improve the Prognosis of Patients with Chronic Myelogenous Leukemia in Blast Crisis

Contact Info

Product

Resources

About